Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

BioCryst Pharmaceuticals Inc

+ Add to Watchlist

BCRX:US

10.0600 USD 0.2200 2.14%

As of 17:20:00 ET on 03/03/2015.

Snapshot for BioCryst Pharmaceuticals Inc (BCRX)

Open: 10.2200 Day's Range: 10.0300 - 10.2600 Volume: 572,121
Previous Close: 10.2800 52wk Range: 7.2900 - 14.6200 1-Yr Rtn: -18.94%

Stock Chart for BCRX

No chart data available.
  • BCRX:US 10.0600
  • 1D
  • 1M
  • 1Y
10.2800
Interactive BCRX Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for BCRX

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -0.6794
Est. EPS (USD) (12/2015) -0.8340
Est. PEG Ratio -
Market Cap (M USD) 727.54
Shares Outstanding (M) 72.32
30 Day Average Volume 787,540
Price/Book (mrq) 8.6625
Price/Sale (ttm) 49.8168
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/07/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for BCRX

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for BCRX

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops small-molecule novel pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases & cancer. The Company has late-stage compounds in development & continues to discover additional compounds & to progress them to meet the unmet medical needs of patients and physicians.

Jon P StonehousePresident/CEOThomas R Staab II "Tom"Senior VP/CFO/Acctg Ofcr
Lynne PowellSenior VP/Chief Commercial OfcrWilliam P SheridanSenior VP/Chief Medical Ofcr
More Company Profile & Key Executives for BCRX

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil